Ligand forecasts Q2 revenue to exceed recent guidance

|About: Ligand Pharmaceuticals... (LGND)|By:, SA News Editor

Ligand Pharmaceuticals (NASDAQ:LGND) expects Q2 revenues to come in at ~$10.6M, up from its May 7 guidance of $9.0M - 9.5M.

Separately, the BOD approves a $10M stock repurchase program to be executed over the next 12 months.